Romvimza, TPO receptor agonist class
Symptomatic tenosynovial giant cell tumor in adults for whom surgical resection would cause worsening functional limi… · Oncology (tenosynovial giant cell tumor)
About Romvimza
Romvimza (vimseltinib) is manufactured by Deciphera Pharmaceuticals (an Ono Pharmaceutical company) and indicated for ITP. It is an Oral CSF1R tyrosine kinase inhibitor (30 mg twice weekly) approved by the US FDA in 2025 and may be accessible to international patients through Named Patient Program or personal-import pathways.
How Reserve Meds coordinates Romvimza
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Romvimza for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Romvimza is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Romvimza in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), real costs in local currency and USD, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Romvimza
Submit a 60-second intake. Our clinical team will reach out as our first cohort opens with case-specific feasibility, timeline, and a formal quote.